Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jul;35(7):3842-3857.
doi: 10.1007/s00330-024-11269-3. Epub 2025 Jan 8.

GOLD grade-specific characterization of COPD in the COSYCONET multi-center trial: comparison of semiquantitative MRI and quantitative CT

Affiliations
Comparative Study

GOLD grade-specific characterization of COPD in the COSYCONET multi-center trial: comparison of semiquantitative MRI and quantitative CT

Philip Konietzke et al. Eur Radiol. 2025 Jul.

Abstract

Objectives: We hypothesized that semiquantitative visual scoring of lung MRI is suitable for GOLD-grade specific characterization of parenchymal and airway disease in COPD and that MRI scores correlate with quantitative CT (QCT) and pulmonary function test (PFT) parameters.

Methods: Five hundred ninety-eight subjects from the COSYCONET study (median age = 67 (60-72)) at risk for COPD or with GOLD1-4 underwent PFT, same-day paired inspiratory/expiratory CT, and structural and contrast-enhanced MRI. QCT assessed total lung volume (TLV), emphysema, and air trapping by parametric response mapping (PRMEmph, PRMfSAD) and airway disease by wall percentage (WP). MRI was analyzed using a semiquantitative visual scoring system for parenchymal defects, perfusion defects, and airway abnormalities. Descriptive statistics, Spearman correlations, and ANOVA analyses were performed.

Results: TLV, PRMEmph, and MRI scores for parenchymal and perfusion defects were all higher with each GOLD grade, reflecting the extension of emphysema (all p < 0.001). Airway analysis showed the same trends with higher WP and higher MRI large airway disease scores in GOLD3 and lower WP and MRI scores in GOLD4 (p = 0.236 and p < 0.001). Regional heterogeneity was less evident on MRI, while PRMEmph and MRI perfusion defect scores were higher in the upper lobes, and WP and MRI large airway disease scores were higher in the lower lobes. MRI parenchymal and perfusion scores correlated moderately with PRMEmph (r = 0.61 and r = 0.60) and moderately with FEV1/FVC (r = -0.56).

Conclusion: Multi-center semiquantitative MRI assessments of parenchymal and airway disease in COPD matched GOLD grade-specific imaging features on QCT and detected regional disease heterogeneity. MRI parenchymal disease scores were correlated with QCT and lung function parameters.

Key points: Question Do MRI-based scores correlate with QCT and PFT parameters for GOLD-grade specific disease characterization of COPD? Findings MRI can visualize the parenchymal and airway disease features of COPD. Clinical relevance Lung MRI is suitable for GOLD-grade specific disease characterization of COPD and may serve as a radiation-free imaging modality in scientific and clinical settings, given careful consideration of its potential and limitations.

Keywords: Chronic obstructive pulmonary disease; Computed tomography; Magnetic resonance imaging; Pulmonary emphysema.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Guarantor: The scientific guarantor of this publication is Philip Konietzke. Conflict of interest: P.K. has no relevant relationships. O.W. airway analysis technology is licensed to Imbio, LLC. S.M.F.T. has no relevant relationships. S.N. has no relevant relationships. F.W. has no relevant relationships. M.K. employee at Boehringer Ingelheim. B.J.J. has no relevant relationships. C.F.V. grants or contracts from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, Grifols, GlaxoSmithKline, and Novartis; consulting fees from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Nuvaira; payment or honoraria for lectures/presentations from Aerogen, AstraZeneca, Boehringer Ingelheim. R.A.J. has no relevant relationships. H.-U.K. Bayer provided consumables to the consortium; the institution receives payment from Siemens, Philips, and Boehringer Ingelheim; consulting fees to the author from Median; and payment or honoraria for lectures/presentations to the author from Siemens, Philips, Boehringer Ingelheim, MSD, and Sanofi. C.P.H. grants/contracts from Siemens (2012–2014), Pfizer (2012–2014), MeVis (2012, 2013), Boehringer Ingelheim (2014), and German Center for Lung Research (2011ff); consulting fees from Schering-Plough (2009 and 2010), Pfizer (2008–2014), Basilea (2008, 2009, and 2010), Boehringer Ingelheim (2010–2014), Novartis (2010, 2012, and 2014), Roche (2010), Astellas (2011 and 2012), Gilead (2011–2015), MSD (2011–2013), Lilly (2011), Intermune (2013–2014), and Fresenius (2013 and 2014); lecture fees from Gilead (2008–2014), Essex (2008, 2009, and 2010), Schering-Plough (2008, 2009, and 2010), AstraZeneca (2008–2014 and 2022), Lilly (2008, 2009, and 2012), Roche (2008 and 2009), MSD (2009–2014), Pfizer (2010–2014), Bracco (2010 and 2011), MEDA Pharma (2011), Intermune (2011–2014), Chiesi (2012), Siemens (2012), Covidien (2012), Pierre Fabre (2012), Boehringer Ingelheim (2012, 2013, and 2022), Grifols (2012), Novartis (2013–2016), Basilea (2015 and 2016), and Bayer (2016); patent: Method and Device For Representing the Microstructure of the Lungs. IPC8 Class: AA61B5055FI, PAN: 20080208038, Inventors: W Schreiber, U Wolf, AW Scholz, C.P.H.; participation on a data safety monitoring board or advisory board: Schering-Plough (2009 and 2010), Pfizer (2008–2014), Basilea (2008, 2009, and 2010), Boehringer Ingelheim (2010–2014, 2022ff), Novartis (2010, 2012, and 2014), Roche (2010), Astellas (2011 and 2012), Gilead (2011–2015), MSD (2011–2013), Lilly (2011), Intermune (2013–2014), Fresenius (2013 and 2014); leadership or fiduciary roles: chest working group of the German Roentgen Society (national guidelines: bronchial carcinoma, mesothelioma, COPD, screening for bronchial carcinoma, CT and MRI of the chest, pneumonia); consultant of ECIL-3, ECCMID, EORTC/MSG (guideline for diagnosis of infections in immunocompromised hosts); founding member of the working team in infections in immunocompromised hosts of the German Society of Hematology/Oncology (guideline for diagnosis of infections in immunocompromised hosts); faculty member of European Society of Thoracic Radiology (ESTI), European Respiratory Society (ERS), and member in EIBALL (European Imaging Biomarkers Alliance); editor of Medizinische Klinik, Intensivmedizin und Notfallmedizin at Springer publishing; stock/stock options GSK. B.J.J. has no relevant relationships. M.O.W. Bayer provided contrast material for MRI examinations; study grants were paid to institutions from Vertex Pharmaceuticals and Boehringer Ingelheim; and consultancy fees were paid to institutions from Vertex Pharmaceuticals and Boehringer Ingelheim. J.B. Siemens Healthineers helped with MRI protocol design; Bayer provided contrast material used in the study; payment for honorarium for presentation at a workshop from Roche, Boehringer Ingelheim, and Fuji; and president of the European Society of Thoracic Imaging 2022–2023. Statistics and biometry: No complex statistical methods were necessary for this paper. Informed consent: Written informed consent was obtained from all subjects (patients) in this study. Ethical approval: Institutional ethics committee approval was obtained (Ethik-Kommission der Medizinischen Fakultät der Universität Heidelberg, S-656/2012) and all subjects gave their written informed consent prior to the study conduct. Study subjects or cohorts overlap: Some study subjects or cohorts have been previously reported in https://doi.org/10.1007/s00330-024-10610-0 (Phenotyping of COPD with MRI in comparison to same-day CT in a multi-center trial) and “COPD phenotyping based on QCT” (under review). Methodology: Prospective Observational Multicenter study

Figures

Fig. 1
Fig. 1
Patient recruitment flowchart
Fig. 2
Fig. 2
MIR airway pathologies. A, B Transversal and coronal post-contrast VIBE images showing airway wall thickening of the right lower lobe bronchi (white arrows). C, D Transversal and coronal post-contrast VIBE images showing a tree-in-bud sign in the right upper lobe (white arrows). E, F Transversal and coronal T2 HASTE images showing bronchiectasis and associated wall thickening in both lower lobes (white arrows). G, H Coronal post-contrast VIBE images during inspiration (G) and expiration (H) with the expiratory collapse of the left main bronchus (white arrows)
Fig. 3
Fig. 3
Box plots for quantitative CT parameters. Box plots of the parenchymal disease parameters TLV, PRM (PRMfSAD, PRMEmph, and PRMAbnormal), MRI parenchymal and perfusion defect scores, and the airway disease parameters WP (WP1–2, WP3–5, and WP6–10) and MRI central, large and SAD scores for the COPD stages risk COPD–GOLD1–4. Boxes indicate the 25–75th percentile, whiskers indicate the 5th and 95th percentile, and individual outliers are indicated by white-filled circles
Fig. 4
Fig. 4
GOLD stage-specific imaging characteristics in QCT and MRI. A1A5 Quantitative CT images with parametric response imaging (PRM) with normal lung (green = PRMNormal), functional SAD (yellow = PRMfSAD), and emphysema (red = PRMEmph). Note: air trapping and emphysema increase with the GOLD stage. B1B5 Perfusion MRI images showing homogeneous lung signal in GOLD1 and extensive perfusion defects (white cross) in GOLD4. Note: MRI perfusion defects correspond to CT emphysema. C1C5 Segmented airway tree on CT (blue = low WP and red = high WP). D1D5 Axial images of lobe bronchi on CT with segmented airway walls with the highest WP in GOLD3. E1E5 Transverse T1 VIBE images of lobe bronchi on MRI. Note: assessment of the airway with MRI is much more challenging than with CT
Fig. 5
Fig. 5
Spearman rank order correlation coefficients. Spearman rank order correlation coefficients were calculated between semiquantitative MRI scores for parenchymal disease (parenchymal and perfusion defect scores), QCT PRM (PRMfSAD, PRMEmph), and the ratio of FEV1/FVC. In addition, semiquantitative MRI scores for central, large, and SAD were correlated with QCT WP pooled for central (WP1–2), large (WP3–5), subsegmental (WP6–10) airways, and FEV1/FVC. Spearman’s r correlation coefficients are given in each panel. Solid lines indicate the linear regression

Similar articles

References

    1. Agusti A, Celli BR, Criner GJ et al (2023) Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med 207:819–837 - PMC - PubMed
    1. Lynch DA, Al-Qaisi MA (2013) Quantitative computed tomography in chronic obstructive pulmonary disease. J Thorac Imaging 28:284–290 - PMC - PubMed
    1. Coxson HO, Leipsic J, Parraga G, Sin DD (2014) Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. Am J Respir Crit Care Med 190:135–144 - PubMed
    1. Labaki WW, Martinez CH, Martinez FJ et al (2017) The role of chest computed tomography in the evaluation and management of the patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 196:1372–1379 - PMC - PubMed
    1. Gould GA, MacNee W, McLean A et al (1988) CT measurements of lung density in life can quantitate distal airspace enlargement—an essential defining feature of human emphysema. Am Rev Respir Dis 137:380–392 - PubMed